{"id":"W2030714208","doi":"10.1038/pcan.2014.24","title":"An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study","year":2014,"lang":"en","type":"article","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Bicalutamide; Medicine; Discontinuation; Antiandrogen; Urology; Prostate cancer; Clinical endpoint; Androgen; Internal medicine; Androgen deprivation therapy; Goserelin; Randomized controlled trial; Cancer; Androgen receptor; Hormone","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001129787,0.001681869,0.001894705,0.000489333,0.0005454313,0.0008965231,0.001259375,0.001353307,0.007216525],"category_scores_gemma":[0.001161329,0.0006362491,0.001186957,0.0004835807,0.00126335,0.0009040548,0.0003714299,0.00354132,0.001477871],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001915493,"about_ca_system_score_gemma":0.002355718,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01365766,"about_ca_topic_score_gemma":0.03987512,"domain_scores_codex":[0.9995358,0.0001873695,0.00001571902,0.00008434676,0.00006069802,0.0001161835],"domain_scores_gemma":[0.9992213,0.0001047083,0.00008327192,0.00006068124,0.00007051019,0.0004595003],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9104723,0.02430622,0.001850956,0.0005294699,0.001149187,0.00009675597,0.0002098079,0.001036754,0.01048806,0.0002393642,0.006373942,0.04324721],"study_design_scores_gemma":[0.8798317,0.1046147,0.01030358,0.00003366638,0.0004535399,0.0001202122,0.00008384849,0.0008050596,0.0007352758,0.0003005081,0.002675584,0.00004237184],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9851248,0.003072443,0.0004522315,0.001006278,0.000310217,0.002671127,0.002921588,0.0001719716,0.004269218],"genre_scores_gemma":[0.9848331,0.001893452,0.001381936,0.001629653,0.0002241211,0.001765696,0.00408818,0.0000562329,0.004127715],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01365766,"threshold_uncertainty_score":0.02715635,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06466855488777716,"score_gpt":0.4243131971048261,"score_spread":0.3596446422170489,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}